Risk factors for non-responsiveness to 5-aminosalicylic acid in patients with ulcerative colitis identified using retrospective clinical study and Mendelian randomization

被引:0
作者
Ye, Zhi-Ning [1 ,2 ]
Liu, Xin-Tian [1 ,2 ]
Gu, Yue-Ming [1 ,2 ]
Mao, Shu-Xian [3 ,4 ]
Liang, Dan-Hong [1 ,2 ]
Zhan, Kai [1 ,2 ]
Lei, Hao-Qiang [5 ]
Huang, Shao-Gang [3 ,4 ]
机构
[1] Guangzhou Univ Chinese Med, Affiliated Dongguan Hosp, Dongguan, Peoples R China
[2] Guangzhou Univ Chinese Med, Clin Coll 9, Dongguan, Peoples R China
[3] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Gastroenterol, 16 Airport Rd, Guangzhou 510120, Peoples R China
[4] Guangdong Clin Res Acad Chinese Med, Guangzhou, Peoples R China
[5] Huangpu Peoples Hosp Zhongshan, Zhongshan, Peoples R China
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
基金
中国国家自然科学基金;
关键词
Ulcerative colitis; 5-Aminosalicylic acid; Responsiveness; Allergy; Aspartate aminotransferase-to-alanine aminotransferase ratio; Inhibitor of nuclear factor kappa-B kinase subunit alpha; INFLAMMATORY-BOWEL-DISEASE; MESALAZINE; POLYMORPHISMS; ASSOCIATION;
D O I
10.1038/s41598-025-89620-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This study aimed to identify risk factors and potential targets associated with non-responsiveness to 5-Aminosalicylic acid (5-ASA) in patients with ulcerative colitis (UC). Patients with mild to moderate UC were grouped based on their responsiveness to 5-ASA. Regression analysis was conducted to identify risk factors for non-responsiveness, while Mendelian randomization (MR) analysis was used to evaluate the potential targets. Among 50 patients (11 non-responders and 39 responders), non-responders exhibited higher incidences of fever, back pain, allergy history, and ankylosing spondylitis, as well as elevated monocyte count and alanine aminotransferase (ALT) level, but a lower aspartate aminotransferase-to-ALT (AST/ALT) ratio (all P < 0.05). Allergy history was a risk factor (OR 140.50, P = 0.021), while a high AST/ALT ratio was a protective factor (OR 0.001, P = 0.023) for non-responsiveness. The area under the receiver operating characteristic curve for the AST/ALT ratio was 0.80. MR analysis showed that inhibition of the inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) by 5-ASA, targeting ALT, increased the risk of UC (OR 1.02, P = 0.002). Our findings suggested that allergy history and the AST/ALT ratio were associated with non-responsiveness to 5-ASA, and CHUK was identified as a potential target for ALT-related non-responsiveness.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] RANDOMIZED OPEN CLINICAL-TRIAL OF 4-AMINOSALICYLIC ACID (4-ASA) AND 5-AMINOSALICYLIC ACID (5-ASA) ENEMAS IN DISTAL ULCERATIVE-COLITIS
    MARTEAU, P
    HALPHEN, M
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1995, 19 (01): : 31 - 35
  • [32] 5-Aminosalicylic Acid Released from Mesalazine Tablet-Comparison of Pharmacokinetic Parameters between Japanese Patients with Ulcerative Colitis and Healthy Adults
    Mitsuyama, K.
    Harada, K.
    Yamasaki, H.
    Kuwaki, K.
    Masuda, J.
    Tsuruta, O.
    Sata, M.
    ASIAN JOURNAL OF CHEMISTRY, 2012, 24 (08) : 3357 - 3361
  • [33] STEADY-STATE PHARMACOKINETICS OF A NEW 4-GRAM 5-AMINOSALICYLIC ACID RETENTION ENEMA IN PATIENTS WITH ULCERATIVE-COLITIS IN REMISSION
    ALMER, S
    NORLANDER, B
    STROM, M
    OSTERWALD, H
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1991, 26 (03) : 327 - 335
  • [34] Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial
    Shen, Zhaofeng
    Zheng, Kai
    Zou, Jiandong
    Gu, Peiqing
    Xing, Jing
    Zhang, Lu
    Zhu, Lei
    Shen, Hong
    TRIALS, 2021, 22 (01)
  • [35] Effect of weekend 5-aminosalicylic acid (Mesalazine) enema as maintenance therapy for ulcerative colitis: Results from a Randomized controlled study
    Yokoyama, Hiroshi
    Takagi, Sho
    Kuriyama, Shinichi
    Takahashi, Shuichiro
    Takahashi, Hiroki
    Iwabuchi, Masahiro
    Takahashi, Seiichi
    Kinouchi, Yoshitaka
    Hiwatashi, Nobuo
    Tsuji, Ichiro
    Shimosegawa, Tooru
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (09) : 1115 - 1120
  • [36] No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study
    Mak, Joyce W. Y.
    Yuen, Nobel T. K.
    Yip, Terry C. F.
    Lam, Ray H. M.
    Lam, Brian K. H.
    Cheng, Cherry T. Y.
    Wong, Grace L. H.
    Chan, Francis K. L.
    Ng, Siew C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (07) : 1284 - 1289
  • [37] Clinical Characteristics and Risk Factors for Pneumocystis Jirovecii Pneumonia during Immunosuppressive Treatment in Patients with Ulcerative Colitis: A Retrospective Study
    Kojima, Kentaro
    Sato, Toshiyuki
    Uchino, Motoi
    Yokoyama, Yoko
    Takagawa, Tetsuya
    Ohda, Yoshio
    Hida, Nobuyuki
    Watanabe, Kenji
    Hori, Kazutoshi
    Miwa, Hiroto
    Ikeuchi, Hiroki
    Nakamura, Shiro
    Shimizu, Masahito
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2020, 29 (02) : 167 - 173
  • [38] COATED ORAL 5-AMINOSALICYLIC ACID (CLAVERSAL) IS EQUIVALENT TO SULFASALAZINE FOR REMISSION MAINTENANCE IN ULCERATIVE-COLITIS - A DOUBLE-BLIND-STUDY
    ARDIZZONE, S
    PETRILLO, M
    MOLTENI, P
    DESIDERI, S
    PORRO, GB
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 21 (04) : 287 - 289
  • [39] PHARMACOKINETICS AND TOXICITY OF HIGH-DOSE TOPICAL COLONIC 5-AMINOSALICYLIC ACID THERAPY IN PATIENTS WITH SEVERELY ACTIVE TOTAL ULCERATIVE-COLITIS
    SCHMASSMANN, A
    FEHR, HF
    LOCHER, J
    KLOTZ, U
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1993, 5 (11) : 927 - 934
  • [40] Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice
    Bai, Xia Yan
    Yan, Yan
    Wang, Lin
    Zhao, Lan Gui
    Wang, Ke
    DRUG DELIVERY, 2016, 23 (06) : 1926 - 1932